Evaluation of Sickle Cell Liver Disease
- Sickle cell disease changes the shape of red cells. This makes them more likely to break down as they get stuck in small blood vessels. This leads to low red cell count and also damage to small blood vessels that supply many organs. One of the affected organs is the liver. Sickle cell disease and its treatment through blood transfusion can lead to significant liver damage. This disease also can cause the liver to regrow abnormally after damage. This can cause high blood pressure in the liver. Researchers want to know if curing sickle cell disease with a stem cell transplant improves liver damage.
- To explore specific factors that improve or worsen sickle cell liver disease after a stem cell transplant.
- Adults ages 18 and older with sickle cell liver disease.
- Participation will take approximately 7 days over 2 years.
- Visit 1: participants will be screened with medical history and review of current treatment regimen.
- Visit 2: participants will return to the clinic for explanation of the study and physical exam. They will also have blood and urine tests, and scans of the liver.
- All participants will have a 2-night stay at the clinic. They will have a liver biopsy and a test of liver pressure. They will be sedated and a tube will be inserted in a vein in their neck.
- Participants who have a stem cell transplant will have a second biopsy about 18 months later.
- Over the 2-year study period, participants will have blood drawn 2 4 times and stool samples collected 2 times.
Sickle Cell Disease
|Official Title:||Evaluation of Sickle Cell Liver Disease|
- Histological evidence of regression of liver disease in stem cell transplanted sickle cell patients measured by degree of improvement in Deugniers and HAI score. [ Time Frame: 1 year post transplant ] [ Designated as safety issue: No ]
- Clinical evidence of regression of liver disease in transplanted sickle cell patients. Evaluate relationship between change in liver disease, bile acids, microbiome and prevalence of infection in SCD. [ Time Frame: 12-18 months post transplant ] [ Designated as safety issue: No ]
- Effect of transplantation on causes and markers of liver related mortality in SCD patientsHistological improvement in liver fibrosis score post stem cell transplant [ Time Frame: 12-18 months post transplant ] [ Designated as safety issue: No ]
|Study Start Date:||August 2013|
|Estimated Study Completion Date:||May 2018|
|Estimated Primary Completion Date:||May 2018 (Final data collection date for primary outcome measure)|
Sickle cell disease (SCD) causes multi-organ dysfunction and early death in affected individuals. Many succumb to complications of chronic organ dysfunction and eventual organ failure one of which is the liver.
Spectrum of sickle cell liver disease ranges from hepatic sequestration crisis, intrahepatic cholestasis, gallstones, non-cirrhotic portal hypertension, chronic sickle hepatopathy and cirrhosis to complications of the treatment of the disease including secondary iron overload and viral hepatitis. Though liver transplantation has been performed for SC-induced liver failure, a crude mortality rate of 60% makes it a poor choice. It is therefore imperative to identify patients with liver dysfunction and damage for possible early intervention.
Stem cell transplant is currently the only cure for SCD and at the NIH SCD hepatopathy is one of the indications for transplant. It is currently not known if stem cell transplant reverses SCD liver disease hence we intend to study and compare the nature of SCD liver disease pre and post stem cell transplant and in transplant ineligible patients. All SCD patients will be screened for liver disease prior to enrollment including fibroscan evaluation. Primary end point is histological evidence of regression of liver disease. Hence all patients in the transplant eligible arm will undergo liver biopsy pre and 12-18 months post transplant. Transplant ineligible patients will be offered liver biopsy when clinically indicated. Patients that have already undergone transplant will be included and their data evaluated retrospectively. Serum and plasma, liver tissue and stool samples will be evaluated extensively for parameters such as liver function tests, iron metabolism, clotting factors, and inflammatory markers including microbial products. The intention of the study is to use sickle cell disease as a model of predicting markers of progression and regression of liver disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01950429
|Contact: Vanessa Haynes-Williams, R.N.||(301) email@example.com|
|Contact: Hawwa Alao, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Hawwa Alao, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|